>[!Most common pediatric brain tumor]-
#peds #cns
>**Pilocystic astrocytoma**
>_33% PA, 15% medullo_

>[!Dermatomes]-
>#anatomy
>**T4: Nipple
>T10: Umbilicus
>L1: Inguinal crease**
>_Xiphoid at level of T10_

>[!Bone scan indications]-
#prostate
>**T1+PSA>20
>T2+PSA>10
>GS8+
>T3+
>Symptomatic**

>[!ECOG 1484 dose if PR to 8c CHOP: NHL]-
#lymphoma
>**40 Gy**

>[!HIF1a relationship to O2 levels]-
#radbio
>**inverse**

>[!FIGO stage IIIA]-
#gyn
>**distal 1/3rd vaginal extension, no parametrial invasion**

>[!tumor markers for mets]-
#breast
>**CEA, CA 15-3, CA 27.29**
>_not CA 19.9_

>[!RILD symptoms]-
#gi
>**anicteric ascites, hepatomegaly, elevated alkPhos**
>_Dex is not SOC: diuretics, paracentesis_

>[!NRG term for dose deviation event]-
#physics
>**medical event**
>_not reportable event_

>[!NCIC/EORTC effect of cc/adj Temodar to 40/15 for GBM]-
#cns
>**worse OS**
>_by 1.5 months_

>[!GTV dosimetric factor correlating to risk for LF]-
#mets
>**Dmin <14**

>[!melanoma response to RAF inhibitors]-
#melanoma
**regression followed by accelerated tumor regrowth**

>[!result of MRC TE-19]-
#gct
>**decreased 2nd germ cell tumors with carboplatin**
>_80% relative risk reduction for contralateral germ cell tumors_

>[!Gem/Cis or cystectomy first for MIBC]-
#bladder
>**nAdj Gem/Cis**
>_more eveidence than for Adj_

>[!SCID mutation in NHEJ machinery]-
#radbio
>**Artemis**
>_details_

>[!predominate process for energy loss of 12 MeV ein low Z]-
#physics
>**inelastic collisions with atomic electrons**
>_inelastic with nucleus = brem_

>[!proteins associated with autophagy]-
#radbio
>**protein kinases**
>_Bcl-2, capsases, cytochrome C only in apoptosis_

>[!physiologic function of autophagy]-
#radbio
>**protects against metabolic stress**
>_which prevents genomic instability -> less cancer_

>[!highest tissue weighting factor]-
#radbio
>**lung**

>[!best application of PARP inhibitors]-
#radbio
>**chemosensitization**
>_makes other chemos and RT more effective_

>[!ENI stations for preop GE junction]-
#gi
>**gastrohepatic and celiac**
>_not superior mesenteric_

>[!FIGO III vagina]-
#gyn
>**LNs**
>_or pelvic sidewall_

>[!results of Malmstrom trial (60 v 34 v TMZ)]-
#cns
>**60 worse than 34**

>[!does PSA bounce or failure happen first]-
#prostate
>**bounce**
>_17 vs 34 months_

>[!TG-142 monthly, yearly dose output constancy]-
#physics
>**2%, 1%**

>[!infusional or bolus 5FU for rectal cancer?]-
#gi
>**infusional**

>[!cellular swelling -> membrane rupture]-
#radbio
>**necrosis**
>_not apoptosis which is more organized_

>[!digital vs film mammography]-
#breast
>**digital only more sensitive for young, dense breasts**
>_otherwise, equivolent_

>[!FDA recommended endpoints for new drugs]-
#radbio
>**time to progression, PFS, DFS, EFS**

>[!neutron RBE increases or decreases with dose relative to Xrays]-
#radbio
>**decreases**
> ![[img_TXIT studying_neutron-rbe.png#invert]-]-

>[!histone modification after ds-DNA breaks]-
#radbio
>**Phosphorylation**
>_of H2AX by ATM_

>[!extrahepatic cholangiocarcinoma with bile duct invasion only]-
#gi
>**T2**
>![[img_TXIT studying_cholangio-staging.png#invert]-]-

>[!Impower133, CASPIAN drugs]-
#lung
>**atezo, durva**

>[!dose for permanent sterility in males, females]-
#radbio
>**6Gy, 12Gy prepuberty/2Gy postpuberty**

>[!10y risk of progression of SBP to MM]-
#misc
>**65-85%**

>[!dosing for M1 Medulo]-
#peds #cns
>**36/20 CSI -> 18/10 boost resection bed**
> _high risk_

>[!which is the linear component? alpha or beta]-
#radbio
>**alpha**

>[!adequate _fixed_ margins for SCC of vulva]-
#gyn
>**8mm**
>_1cm clinical marigin due to shrinkage during fixation_

>[!DLBCL of this site -> CNS relapse]-
#lymphoma
>**adrenal gland**
>_from German High-Grade NHL_
>

>[!first step in ss-DNA repair]-
#radbio
>**end processing by polynucleotide kinase**

>[!having more p or n in a nucleus is more stable?]-
#physics
>**neutrons**
>_also even numbers of p and n_

>[!IMPORT-LOW 5y LR in non-high risk pts]-
#breast
>**1%**

>[!QUANTEC volumetric bladder constraints]-
#prostate #gu
>
>| V   | %   |
>| --- | --- |
>| 65  | 50  |
>| 70  | 35  |
>| 75  | 25  |
>| 80  | 15  |
>
>[!systemic therapy for unresectable desmoids]-
#misc
>**tamoxifen**
>_also NSAIDS, chemo, TKIs_

>[!10y DFS for MIBC after definitive CCRT]-
#bladder #gu
>**40%**
>_from RTOG 8802, MGH RR_

>[!Stockholm III trial design]-
#gi
>**LCRT w/ delay**
>**SCRT w/ delay**
>**SCRT w/out delay**
>_no chemo_

>[!rate of supraclav recurrence in N1 breast cancer (no RT)]-
#breast 
>**<3%**
>_per MA.20, EORTC 22922_

>[!maximum dose grid size for SBRT]-
#physics 
>**2mm**

>[!stage I seminoma s/p orchiectomy 15y relapse and salvage rate]-
#gu #gct 
>**20, 100%**

>[!T2 a vs b Lung cancer]-
#lung
>**Â±4 (a=4)**

>[!COG 205 preopRT dose]-
#gyn 
>**5760cGy/32fx**

>[!RTOG 0630 preop RT CTV volume definition]-
#sarcoma
>**GTV = T1+**
>_CTV expansions based on grade_

>[!group with highest prevalance of oral HPV infection]-
#hn
>**men 55-59yo**

>[!results of RTOG 0813 SBRT dose-finding]-
#lung
>**2y LC 85-90% at 11.5 & 12 Gy/fx**

>[!Tao Intrahepatic cholangio 3y LC rates at high BED]-
#gi 
>**78%**
>_bed >80.5Gy_

>[!non-classic RILD definition]-
#gi 
>**increase in CP score by 2 or ALBI by 1**
>_more score changes than symptoms_

>[!cause of death in bilateral retinoblastoma]-
#peds #misc 
>**other cancers**

>[!histology & node type of gastric cancer most likely to benefit from postop CCRT per ARTIST ]-
#gi 
>**intestinal type, N+**

>[!results of SCLC CONVERT trial. 66 QD or 45 BID?]-
#lung 
>**BID due to lack of superiority over QD**

>[!TV (treated volume) definition per ICRU-83]-
#physics 
>**V98%**

>[!penile bulb dose constraint]-
#prostate #gu 
>**mean dose < 52.5Gy**
>_per RTOG 0126_

>[!is BCL2 pro- or anti-apoptotic]-
#radbio 
>**anti-apoptotic**
>_BAX is pro-apoptotic_

>[!question]-
#
>**answer**
>_details_
